Heart attack survivors with preserved heart function may not need long-term beta-blocker therapy, challenging decades of standard cardiac care protocols. This finding could spare millions of patients from unnecessary medications and their associated side effects while maintaining optimal outcomes. The research examined patients who experienced myocardial infarction but retained normal left ventricular ejection fraction, representing roughly half of all heart attack cases. Traditional cardiology guidelines have recommended beta-blockers for virtually all post-MI patients based on older studies that included many patients with weakened heart muscle. The current analysis focused specifically on the subset with ejection fractions above 50 percent, finding no significant mortality reduction from continued beta-blocker use compared to discontinuation or alternative therapies. This represents a meaningful shift from the one-size-fits-all approach that has dominated post-MI care for generations. The implications extend beyond individual patient care to healthcare economics, as beta-blockers carry risks including fatigue, depression, sexual dysfunction, and exercise intolerance that may unnecessarily diminish quality of life. However, this finding requires careful interpretation within the broader evidence base. Previous landmark trials establishing beta-blocker benefits were conducted in an era before modern revascularization techniques and contemporary antiplatelet therapies became standard. The patient population with preserved ejection fraction may indeed represent a lower-risk subset where the marginal benefits of beta-blockade are outweighed by potential harms. Cardiologists will need to weigh this evidence against individual patient factors, as the field moves toward more personalized post-MI management strategies rather than universal prophylactic approaches.